In vivo pH mapping within tumor and kidney have been successfully demonstrated in both preclinical and clinical settings using MRI based imaging modality, known as AcidoCEST. This method uses iodinated contrast agents (ICAs) as exogenous contrast agent which are normally used in CT scans. So far, these methods have mainly utilized CEST contrast from to the amide peaks (~4.2, 5.6 ppm) ICAs. We demonstrate the feasibility of detecting the CEST contrast from both hydroxyl groups (~0.8 ppm) and amide groups (~4.2 ppm) from Iodixanol in the glioma model.
This abstract and the presentation materials are available to members only; a login is required.